FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319600767> ?p ?o ?g. }

• W4319600767 endingPage "1067" @default.
• W4319600767 startingPage "1067" @default.
• W4319600767 abstract "Patients with advanced ovarian cancer (OC) have a detrimental prognosis. The options for systemic treatment of advanced OC in later lines of treatment are limited by the availability of active therapies and their applicability to often fragile, exhausted patients with poor performance status. Metronomic chemotherapy (MC) is a concept of a continuous administration of cytotoxic drugs, which is characterized by multidirectional activity (anti-proliferative, anti-angiogenic, and anti-immunosuppressive) and low toxicity. We have performed a retrospective analysis of consecutive, advanced, chemo-refractory OC patients treated with MC based on single-agent topotecan (1 mg p.o. q2d) or on a topotecan (1 mg q2d) and cyclophosphamide (50 mg p.o. qd) combination (CyTo). Metronomic chemotherapy demonstrated promising activity, with 72% and 86% of patients achieving biochemical or objective disease control and 18% and 27% of patients achieving a biochemical or objective response, respectively. The median PFS in the whole population was 3.65 months, but the median PFS in patients with a biochemical response to MC (18.2% of patients) reached 10.7 months. The study also suggested that overweight or obese patients had significantly better outcomes on MC than patients with BMI <25 kg/m2. This article is the first report in the literature on metronomic chemotherapy based on a topotecan + cyclophosphamide combination (CyTo). The CyTo regimen demonstrated safety, clinical activity, and potential broad clinical applicability in advanced OC patients and will be evaluated in a forthcoming clinical trial." @default.
• W4319600767 created "2023-02-09" @default.
• W4319600767 creator A5022272750 @default.
• W4319600767 creator A5041637532 @default.
• W4319600767 creator A5059778478 @default.
• W4319600767 creator A5060400070 @default.
• W4319600767 creator A5063000124 @default.
• W4319600767 creator A5070929522 @default.
• W4319600767 creator A5073752190 @default.
• W4319600767 creator A5085044939 @default.
• W4319600767 date "2023-02-07" @default.
• W4319600767 modified "2023-09-28" @default.
• W4319600767 title "Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer" @default.
• W4319600767 cites W1767413501 @default.
• W4319600767 cites W1793615273 @default.
• W4319600767 cites W1901579352 @default.
• W4319600767 cites W1913802169 @default.
• W4319600767 cites W1963664515 @default.
• W4319600767 cites W2006350851 @default.
• W4319600767 cites W2013492504 @default.
• W4319600767 cites W2018716798 @default.
• W4319600767 cites W2051960191 @default.
• W4319600767 cites W2068796910 @default.
• W4319600767 cites W2088452019 @default.
• W4319600767 cites W2102306754 @default.
• W4319600767 cites W2106767659 @default.
• W4319600767 cites W2118548073 @default.
• W4319600767 cites W2128011232 @default.
• W4319600767 cites W2137797191 @default.
• W4319600767 cites W2151628822 @default.
• W4319600767 cites W2152246203 @default.
• W4319600767 cites W2156194356 @default.
• W4319600767 cites W2161390044 @default.
• W4319600767 cites W2164520290 @default.
• W4319600767 cites W2170845869 @default.
• W4319600767 cites W2242853197 @default.
• W4319600767 cites W2486161360 @default.
• W4319600767 cites W2551893887 @default.
• W4319600767 cites W2586781596 @default.
• W4319600767 cites W2737389832 @default.
• W4319600767 cites W2800764403 @default.
• W4319600767 cites W2807649309 @default.
• W4319600767 cites W2905577219 @default.
• W4319600767 cites W2951714360 @default.
• W4319600767 cites W2991621188 @default.
• W4319600767 cites W2994977341 @default.
• W4319600767 cites W3013482099 @default.
• W4319600767 cites W3023360011 @default.
• W4319600767 cites W3113531122 @default.
• W4319600767 cites W3160060068 @default.
• W4319600767 cites W3202606573 @default.
• W4319600767 cites W4236289131 @default.
• W4319600767 cites W4280654633 @default.
• W4319600767 cites W4310786966 @default.
• W4319600767 doi "https://doi.org/10.3390/cancers15041067" @default.
• W4319600767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36831410" @default.
• W4319600767 hasPublicationYear "2023" @default.
• W4319600767 type Work @default.
• W4319600767 citedByCount "3" @default.
• W4319600767 countsByYear W43196007672023 @default.
• W4319600767 crossrefType "journal-article" @default.
• W4319600767 hasAuthorship W4319600767A5022272750 @default.
• W4319600767 hasAuthorship W4319600767A5041637532 @default.
• W4319600767 hasAuthorship W4319600767A5059778478 @default.
• W4319600767 hasAuthorship W4319600767A5060400070 @default.
• W4319600767 hasAuthorship W4319600767A5063000124 @default.
• W4319600767 hasAuthorship W4319600767A5070929522 @default.
• W4319600767 hasAuthorship W4319600767A5073752190 @default.
• W4319600767 hasAuthorship W4319600767A5085044939 @default.
• W4319600767 hasBestOaLocation W43196007671 @default.
• W4319600767 hasConcept C121332964 @default.
• W4319600767 hasConcept C121608353 @default.
• W4319600767 hasConcept C126322002 @default.
• W4319600767 hasConcept C142424586 @default.
• W4319600767 hasConcept C143998085 @default.
• W4319600767 hasConcept C2776694085 @default.
• W4319600767 hasConcept C2776755627 @default.
• W4319600767 hasConcept C2780427987 @default.
• W4319600767 hasConcept C2781209748 @default.
• W4319600767 hasConcept C2781413609 @default.
• W4319600767 hasConcept C2908647359 @default.
• W4319600767 hasConcept C71924100 @default.
• W4319600767 hasConcept C87355193 @default.
• W4319600767 hasConcept C90924648 @default.
• W4319600767 hasConcept C98274493 @default.
• W4319600767 hasConcept C99454951 @default.
• W4319600767 hasConceptScore W4319600767C121332964 @default.
• W4319600767 hasConceptScore W4319600767C121608353 @default.
• W4319600767 hasConceptScore W4319600767C126322002 @default.
• W4319600767 hasConceptScore W4319600767C142424586 @default.
• W4319600767 hasConceptScore W4319600767C143998085 @default.
• W4319600767 hasConceptScore W4319600767C2776694085 @default.
• W4319600767 hasConceptScore W4319600767C2776755627 @default.
• W4319600767 hasConceptScore W4319600767C2780427987 @default.
• W4319600767 hasConceptScore W4319600767C2781209748 @default.
• W4319600767 hasConceptScore W4319600767C2781413609 @default.
• W4319600767 hasConceptScore W4319600767C2908647359 @default.
• W4319600767 hasConceptScore W4319600767C71924100 @default.

• next